Powder lyophilized for preparing solution for
Injection / solution for injection 20 mg/ml
Trade name: Cytarabine.
International nonproprietary name: Cytarabine.
Pharmaceutical form: Lyophilized powder injection, 100 mg, 1000 mg. Porous white mass in form of tablet
Solutions for injections 20 mg/ml.
Composition: each vial contains:
Active substance: cytarabine 1000 mg, 100 mg.
Excipients: low –molecular polyvinyl pyrrolidone medical grade Mr 12600 ± 2700 (povidone).
ATC code: L01BC01.
Indications for use:
► Lymphoblast and myeloblast leukemia.
► Chronic myeloleukemia.
► Erythroleukemia, lymphogranulomatosis.
► Non- Hodgkin’s lymphoma.
► Syndrome of bone marrow dysplasia.
The cytarabine high- dose therapy is applied within the induction and consolidation programs under primary acute lymphoblast and myeloblast leukemia; under secondary leukemia developed either after the preceding cytostatic and/or beam therapy or as a result of the MDS transformation; under primarily resistant forms of acute leukemia; under resistant relapses of acute leukemia; under a blast crisis of chronic myeloleukemia; under resistant Hodgkin’s and non- Hodgkin’s lymphomas.
